Patent Grant
11435361
An autoantibody is an antibody manufactured by an individual's immune system that is directed against an antigen of the individual's own proteins. Antibodies are normally produced in response to a foreign protein or substance within the body, typically a pathogen, which is an infectious organism. Normally, the immune system is able to recognize and ignore the body's own cells and not overreact to non-threatening substances in the environment, such as foods. Sometimes, however, the immune system ceases to recognize one or more of the body's normal constituents as “self”, leading to production of autoantibodies. These autoantibodies attack the body's own cells, tissues, and/or organs, causing inflammation and damage.
Serum autoantibodies have been implicated in a wide variety of neurological diseases and syndromes. Neuron-binding autoantibodies have been detected in sera from individuals exhibiting obsessive compulsive disorder, Sydenham's chorea, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (“PANDAS”), and Hashimoto's encephalopathy. Schizophrenia has also been linked to the appearance of autoantibodies, including several directed against neuronal surface receptors. Systemic lupus erythematosus (“SLE”), known to be caused by antinuclear antibodies, appears to have cognitive and memory loss components consistent with the presence of a subset of anti-DNA antibodies that cross-react with the N-methyl-D-aspartate receptor (“NMDAR”). Also, brain-reactive antibodies in mothers of autistic children elicit behavioral abnormalities in progeny when administered to pregnant mammals.
Moreover, among neurodegenerative diseases, autoantibodies have been found in Parkinson's disease, Autism spectrum disorders, amyotrophic lateral sclerosis, multiple sclerosis, Guillain-Barre syndrome, chronic peripheral neuropathy, optic neuritis, vascular dementia, and Alzheimers disease (“AD”). In the case of AD, there have been numerous reports of patients having high titers of autoantibodies to both non-brain and brain-associated targets, including neuron-binding autoantibodies. Moreover, several specific autoantibody targets have been identified, including aldolase, heavy neurofilament subunit, histone, tubulin, glial fibrillary acid protein, and S-100.
Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disorder of the elderly that is highlighted by a dramatic reduction of memory and cognition and linked to loss of neurons and synapses (Selkoe (2002) Science 298, 789-91). Additional key pathological features include the deposition of amyloid beta (Aβ), especially the 42-amino acid peptide (Aβ42), within neurons, amyloid plaques and in the walls of brain blood vessels, as well as the appearance of neurofibrillary tangles, glial activation and widespread inflammation (Schwab et al. (2008) J Alzheimers Dis 13, 359-69; Thal et al. (2008) Acta Neuropathol 115, 599-609; Weisman et al. (2006) Vitam Horm 74, 505-30). Aβ42 deposition within neurons is initiated early in the course of the disease, precedes amyloid plaque and tangle formation, and temporally and spatially coincides with loss of synapses in human AD and transgenic mouse brains (D'Andrea et al. (2001) Histopathology 38, 120-134; Nagele et al. (2002) J Neurosci 110, 199-211; Gouras et al. (2000) Am J Patho. 156, 15-20). This has led to the proposal that the gradual growth of Aβ deposits may progressively impair the ability of neurons to support their extensive dendritic arbors, thereby contributing to early synaptic loss that eventually becomes apparent through telltale symptoms.
Studies have reported the presence of immunoglobulin (Ig)-immunopositive neurons in histological sections of post-mortem AD brains, which were only rarely observed in comparable brain regions of non-demented, age-matched controls (Stein et al. (2002) J Neuropathol Exp Neurol 61, 1100-8; Bouras et al. (2005) Brain Res Brain Res Rev 48, 477-87; D'Andrea (2003) Brain Res Brain Res Rev 982, 19-30). The presence of specific brain-reactive autoantibodies in the serum of AD patients has also been reported. (Bouras et al. (2005) Brain Res Brain Res Rev 48, 477-87; Kulmala et al. (1987) Exp Aging Res 13, 67-72; Mecocci et al. (1993) Biol Psychiatry 34, 380-5; Mecocci et al. (1995) J Neuroimmunol 57, 165-70; Weksler et al. (2002) Exp Gerontol 37, 971-979).
Autism spectrum disorders (“ASDs”) are a group of disorders in brain development that includes autism, Asperger's syndrome, Rett's disorder, and childhood disintegrative disorder. ASDs are characterized by impairments in social behavior and communication that are usually expressed within the first 36 months of childhood (American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (2000)). A substantial fraction (20-30%) of autism patients undergo a period of autistic regression during which they experience a loss of previously acquired milestones in language and behavioral skills. (Fombonne (2003) JAMA 289, 87-89). Inexplicably, the prevalence of ASD has recently increased dramatically, a finding not due to improved diagnostics, but rather suggesting some environmental causal factor(s). ASDs now affect 1:150 children, and the etiology is largely unknown but likely to be multifactorial (Fombonne, 2003).
Neuropathological and neuroimaging studies of autistic patients have reported increased brain size and weight (Bailey et al. (1998) Psychol Med 25, 63-77; Kemper and Bauman (1998) Neurol Clinic 1, 175-87; Palmen et al. (2004) Brain 127, 2572-2583). Many studies of autistic brains have reported an overall reduction in neuron size and an increased neuron packing density, especially in the hippocampus, subiculum and amygdala (Kemper and Bauman, 1993).
ASDs have been linked to specific brain abnormalities. Neurological observations and neuroimaging studies have provided evidence that many brain regions can be affected in autism, including the cerebellum, cerebral cortex, amygdala, hippocampus, basal ganglia and the brain stem (Akshoomoff et al., 2002; Acosta and Pearl (2004) Semin Pediatr Neurol 11, 205-213). Cerebellar abnormalities are also common in ASD, hallmarked by a scarcity of Purkinje and granule cells (Courchesne et al., 2001).
Autoimmunity and autoantibodies are involved in the pathogenesis of ASDs (Ashwood et al. (2006) J Leukocyte Biol 80, 1-11; Wills et al. (2007) Ann N.Y. Acad Sci 1107, 79-91; Zimmerman et al. (2007) Brain Behav Immun 21, 351-357). The binding of autoantibodies to neurons can disrupt the normal pattern of neurodevelopment at critical stages. Autoantibodies reactive to the brain have been reported in autistic children, and several autoimmune factors including brain-specific autoantibodies, impaired lymphocyte function, abnormal cytokine regulation, and viral associations have been implicated (Singh and Rivas (2004) Neurosci Lett 355, 53-56). For example, Singh and Rivas (2004) have shown that the serum of autistic children contains brain-specific autoantibodies. In a study of 68 autistic children at 4-12 years of age, antibodies to the caudate nucleus, cerebral cortex and cerebellum were detected in 49%, 18% and 9%, respectively, of autistic children, but not in normal children. Another study has shown that children with Tourette syndrome possess anti-striatal antibodies, and influsion of these antibodies into the rat striatum caused neuronal dysfunction similar to Tourette syndrome (Hallet et al. (2000) J Neuroimmunol 111, 195-202). Other anti-brain antibodies have also been found in autistic patients, including antibodies to serotonin receptor, myelin basic protein, axon filament protein, cerebellar neurofilaments, nerve growth factor, brain endothelial proteins and antibodies directed against other unidentified brain proteins.
A strong link between the presence of anti-neuronal autoantibodies and neurological disease has been shown in children in cases following streptococcal infections, such as in obsessive compulsive disorder (OCD), Sydenham's chorea, Tourette syndrome, PANDAS, and paraneoplasia, and in elderly patients with SLE that show both cognitive and memory loss (Swedo et al. (1989) Am J Psychiatry 154, 110-2; Kalume et al. (2004) J Neurosci Res 77, 82-89; Tanaka et al. (2004) J Neurological Sci 217, 25-30). DeGeorgio et al. (2001) Nature Med 11, 1189-1193 and Kowal et al. (2004) Immunity 21, 179-188, report that a subset of anti-DNA antibodies in SLE patients cross-reacts with the NMDA (N-methyl-D-aspartate) subtype of glutamate receptors (NR2a and NR2b) by means of molecular mimicry and induces neuronal injury and death both in vivo and in vitro.
In one embodiment, the present invention provides a method for detecting neurodegenerative disease diagnostic autoantibodies in a subject comprising obtaining a biological sample from the subject, and performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample.
In another embodiment, the present invention provides a method for diagnosing a neurodegenerative disease in a subject comprising obtaining a biological sample from the subject, performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and diagnosing said neurodegenerative disease if one or more of the disease diagnostic autoantibodies is present.
In another embodiment, the present invention provides a method of identifying a subject at risk for developing a neurodegenerative disease comprising obtaining a biological sample from the subject, performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and identifying the subject as at risk for developing said neurodegenerative disease if one or more of the disease diagnostic autoantibodies is present.
In another embodiment, the present invention provides a method of generating a subject-specific, neurodegenerative disease diagnostic autoantibody profile comprising obtaining a biological sample from a subject, performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and generating a subject-specific neurodegenerative disease diagnostic autoantibody profile of the disease diagnostic autoantibodies present in the sample.
Another embodiment of this invention provides a substrate on which one or more autoantigens that are specific for one or more neurodegenerative disease diagnostic autoantibodies are immobilized.
Another embodiment of this invention provides a microarray comprising a substrate on which one or more autoantigens that are specific for one or more neurodegenerative disease diagnostic autoantibodies are immobilized.
Another embodiment of this invention provides a kit for detecting neurodegenerative disease diagnostic autoantibodies.
In accordance with the present invention, it has been discovered that autoantibodies, also known as self-reactive antibodies, are both abundant and ubiquitous in human sera, regardless of age or the presence or absence of disease. Some are brain-reactive; others are reactive to targets in other organs throughout the body. Although some autoantibodies may be vestiges of past diseases and immunological activity, it has been discovered in accordance with the present invention that many autoantibodies are also present in the blood and cerebrospinal fluid as a result of existing or ongoing diseases. It is this latter group that is useful for the early detection and diagnosis of existing diseases.
It has been discovered herein that the presence of active neurodegenerative disease, including both long- and short-term diseases, causes the production and release of cellular products as a result of cell damage related to ongoing pathology, some of which are both cell type- and organ-specific. These released cellular products (many of which are proteins), their break-down fragments and disease-related post-translational modifications enter the blood and lymph circulation, act as antigens, and elicit an immune response. This immune response leads to the production and appearance of a relatively large number of self-reactive autoantibodies in the blood. Cells throughout the body share a vast number of proteins in common, but only a relatively small subset of autoantibodies are specifically reactive to the cells, tissues and organs involved in a particular disease. It has been discovered in accordance with the present invention that this response leads to a disease-specific autoantibody profile that is characteristic for each disease and the specific cell types involved. In addition, in individuals with concurrent diseases, it has been discovered herein that a specific pattern of autoantibodies reflects each of these concurrent, ongoing disease processes.
Additionally, it has been discovered herein that autoantibodies capable of binding to brain-specific targets, including neurons and their supportive glial cells, are common in the blood; in fact they appear to be ubiquitous. Binding of these autoantibodies to neurons and/or glial cells in the brain is harmful to these cells and the functions in which they participate. It not only disrupts normal cellular functions, but also eventually leads to neuron and glial cell death and permanent loss from the brain.
Once inside the brain tissue, autoantibodies are free to bind selectively to any cells within the brain that possess and display the proper target antigens on their surfaces. If the autoantibody target is particularly abundant on a cell surface, the binding of many molecules of autoantibody can crosslink and immobilize this protein. If the target is an important receptor, the target and the cell can be rendered nonfunctional, leading to more global brain functional impairments. When the target cells are neurons, autoantibody binding may lead to neuronal dysfunction that can eventually manifest itself as behavioral, cognitive, memory and motor impairments. When the target is a glial cell that supports neurons, the loss of this support may indirectly compromise the function of neurons. Thus, specific brain-reactive autoantibodies in human sera can put one at risk for specific neurodegenerative diseases. The invention described herein provides a method for the detection of these autoantibodies in human biological samples.
Thus in one embodiment, the present invention provides a method of identifying a subject at risk for developing a neurodegenerative disease comprising obtaining an immunoglobulin-containing biological sample from the subject, performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and identifying the subject as at risk for developing said neurodegenerative disease if one or more of the disease diagnostic autoantibodies is present.
In another embodiment of this invention provides a method for detecting neurodegenerative disease diagnostic autoantibodies in a subject comprising obtaining an immunoglobulin-containing biological sample from the subject, and performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample.
In a preferred embodiment, the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Guillain-Barre syndrome, chronic peripheral neuropathy, optic neuritis, vascular dementia, obsessive compulsive disorder, Sydenham's chorea, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (“PANDAS”), Hashimoto's encephalopathy, schizophrenia, systemic lupus erythematosus, vascular cognitive disorders, stroke, Huntington's disease, neuromyelitis optica, paraneoplastic syndromes, limbic encephalitis, Rasmussen encephalitis, Hashimoto's encephalitis, encephalitis lethargica, stiff person syndrome, post-streptococcal movement disorders, rheumatic fever, gluten enteropathy, ASD, dyslexia, HTLV-1-associated myelopathy/tropical spastic paraparesis, myasthenia gravis, Lambert-Eaton syndrome, and arthrogryposis multiplex congenita.
In a preferred embodiment of the invention, the subject is a human.
In a preferred embodiment of the invention, the immunoglobulin-containing biological sample is serum, whole blood, CSF, saliva, or sputum. A blood sample may be obtained by methods known in the art including venipuncture or a finger stick. CSF may be obtained by methods known in the art including a lumbar spinal tap. To obtain serum from blood, a sample of blood is received and centrifuged at a speed sufficient to pellet all cells and platelets, and the serum to be analyzed is drawn from the resulting supernatant. Sputum and saliva samples may be collected by methods known in the art. The biological samples may be diluted with a suitable buffer.
In a preferred embodiment of the invention, the assay used to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample is performed by contacting the biological sample with one or more autoantigens that are specific for a neurodegenerative disease diagnostic autoantibody under conditions that allow an immunocomplex of the autoantigen and the autoantibody to form, and detecting the presence of the immunocomplex.
Autoantibodies that are specific for a neurodegenerative disease diagnostic autoantibody may be identified by comparing the autoantibodies present in aa immunoglobulin-containing sample from a subject having a neurodegenerative disease with autoantibodies present in an immunoglobulin-containing sample from an age-matched disease-free control subject. The target autoantigens for the autoantibodies present in the sample from the subject having the disease but not present in the sample from the control subject provide the identification of the disease diagnostic autoantibodies. The sample is preferably serum.
For example, protein microarrays containing thousands of full-sized or nearly full-sized human proteins spotted on a single specimen slide may be used to identify autoantibodies in a patient sample that are reactive with the antigen targets on the microarray. Autoantibodies in a control sample may be similarly identified. The patient autoantibody profile may be compared with the control autoantibody profile to determine the disease specific autoantibodies and corresponding autoantigens.
Protein microarrays useful for identifying neurodegenerative disease diagnostic autoantibodies and autoantigens may be made by methods known in the art and are also commercially available. Commercially available protein microarrays include, for example, Invitrogen's ProtoArray® Human Protein Microarray v5.0, which is preferably used in accordance with the Invitrogen ProtoArray® protocol and Immune Response Biomarker Profiling application.
Methods for probing and scanning such protein microarrays, and for determining the diagnostic significance of the resulting data, are known to those of skill in the art and disclosed, for example, by Tibshirani et al. (2002) Proc Natl Acad Sci USA 99, 6567-6572. Once the autoantibodies that are diagnostic for the neurodegenerative disease are identified by the foregoing methods, the corresponding autoantigens are identified and selected for use in the methods of detection and diagnosis.
An autoantigen may comprise a protein antigen, a polypeptide or peptide fragment thereof containing one or more epitopes recognized by the disease diagnostic autoantibody, or an epitope peptidomimetic that is recognized by the disease diagnostic autoantibody. The autoantigens may be purified from natural sources, or produced recombinantly or synthetically by methods known in the art, and may be in the form of fusion proteins. The autoantigens may be produced in vitro using cell-free translation systems. In one preferred embodiment, the autoantigens are produced in a mammalian or insect expression system to ensure correct folding and function. All of these methods may be automated for high throughput production.
Assays and conditions for the detection of immunocomplexes are known to those of skill in the art. Such assays include, for example, competition assays, direct reaction assays and sandwich-type assays. The assays may be quantitative or qualitative. In one preferred embodiment, the assay utilizes a solid phase or substrate to which the autoantigens are directly or indirectly attached, such as a microtiter or microassay plate, slide, magnetic bead, non-magnetic bead, column, matrix, membrane, dipstick, filter, membrane, pin, or sheet, and may be composed of a synthetic material such as polystyrene, polyvinyl chloride, polyamide, or other synthetic polymers, natural polymers such as cellulose, derivatized natural polymers such as cellulose acetate or nitrocellulose, and glass, for example glass fibers. The substrate preferably comprises a plurality of individually addressable autoantigens immobilized on the surface. The individually addressable autoantigens are preferably immobilized on the surface to form an array. The substrates may be used in suitable shapes, such as films, sheets, or plates, or may be coated onto or bonded or laminated to appropriate inert carriers, such as paper, glass, plastic films, or fabrics. In a preferred embodiment, the substrate is a slide or a bead.
Methods for attaching the autoantigens to the support or substrate are known in the art and include covalent and noncovalent interactions. For example, diffusion of applied proteins into a porous surface such a hydrogel allows noncovalent binding of unmodified protein within hydrogel structures. Covalent coupling methods provide a stable linkage and may be applied to a range of proteins. Biological capture methods utilising a tag (e.g., hexahistidine/Ni-NTA or biotin/avidin) on the protein and a partner reagent immobilized on the surface of the substrate provide a stable linkage and bind the protein specifically and in reproducible orientation. In one preferred embodiment, the autoantigens are coated or spotted onto the support or substrate such as chemically derivatized glass. In a more preferred embodiment, nitrocellulose-coated glass slides are used
In one preferred embodiment the autoantigens are provided in the form of an array, and preferably a microarray. Protein microarrays are known in the art and reviewed for example by Hall et al. (2007) Mech Ageing Dev 128:161-167 and Stoevesandt et al (2009) Expert Rev Proteomics 6:145-157, the disclosures of which are incorporated herein by reference in their entireties. Microarrays may be prepared by immobilizing purified autoantigens on a substrate such as a treated microscope slide using a contact spotter or a non-contact microarrayer. Microarrays may also be produced through in situ cell-free synthesis directly from corresponding DNA arrays.
Suitable methods for external production and purification of autoantigens to be spotted on arrays include expression in bacteria, as disclosed for example by Venkataram et al. (2008) Biochemistry 47:6590-6601, in yeast, as disclosed for example by Li et al. (2007) Appl Biochem Biotechnol. 142:105-124, in insect cells, as disclosed for example by Altman et al. (1999) Glycoconj J 16:109-123, and in mammalian cells, as disclosed for example by Spampinato et al. (2007) Curr Drug Targets 8:137-146.
Suitable methods for in situ (“on-chip”) protein production are disclosed, for example, by Ramachandran et al. (2006) Methods Mol. Biol 2328:1-14 and He et al. (2008) Curr. Opin Biotechnol 19:4-9.
Other methods by which proteins are simultaneously expressed and immobilized in parallel on an array surface are also known in the art and may be used in accordance with the present invention. For example, in the Protein In Situ Arrays (PISA) method (He et al. (2001) Nucleic Acids Res 29:e73), proteins are made directly from DNA, either in solution or immobilized, and become attached to the array surface as they are made through recognition of a tag sequence. The proteins are expressed in parallel in vitro utilizing a cell free system, commonly rabbit reticulocyte or E. coli S30, to perform coupled transcription and translation. In this method, protein expression is performed on a surface which is precoated with an immobilizing agent capable of binding to the tag. Thus after each protein is translated, it becomes fixed simultaneously and specifically to the adjacent surface, while the other materials can subsequently be washed away. Microarrays may be produced directly onto glass slides, either by mixing the DNA with the cell free lysate system before spotting or by a multiple spotting technique (MIST) in which DNA is spotted first followed by the expression system.
In the system known as Nucleic Acid Programmable Protein Array (NAPPA) (Ramachandran et al. (2004) Science 305:86-90), transcription and translation from an immobilized (as opposed to a solution) DNA template allow conversion of DNA arrays to protein arrays. In this method, biotinylated cDNA plasmids encoding the proteins as GST fusions are printed onto an avidin-coated slide, together with an anti-GST antibody acting as the capture entity. The cDNA array is then covered with rabbit reticulocyte lysate to express the proteins, which become trapped by the antibody adjacent to each DNA spot, the proteins thereby becoming immobilized with the same layout as the cDNA. This technology generates a protein array in which the immobilized proteins are present together with DNA and a capture agent.
Another suitable method for generating a protein array is the DNA Array to Protein Array (DAPA) method. This method for in situ protein arraying uses an immobilized DNA array as the template to generate ‘pure’ protein arrays on a separate surface from the DNA, and also can produce multiple copies of a protein array from the same DNA template (He et al. (2008) Nature Methods, 5:175-7). Cell-free protein synthesis is performed in a membrane held between two surfaces (e.g., glass slides), one of which is arrayed with DNA molecules while the other surface carries a specific reagent to capture the translated proteins. Individual, tagged proteins are synthesized in parallel from the arrayed DNA, diffuse across the gap and are subsequently immobilized through interaction with the tag-capturing reagent on the opposite surface to form a protein array. Discrete spots which accurately reflect the DNA in position and quantity are produced. Replicate copies of the protein array can be obtained by reuse of the DNA.
Array fabrication methods include robotic contact printing, ink-jetting, piezoelectric spotting and photolithography. For example, purified autoantigens of the invention that are produced and purified externally may be spotted onto a microarray substrate using a flexible protein microarray inkjet printing system (e.g., ArrayJet, Roslin, Scotland, UK) to provide high quality protein microarray production. The precise rows and columns of autoantigens may be converted to detectable spots denoting both the presence and amount of diagnostic autoantibodies that have been bound.
The production of the microarrays is preferably performed with commercially available printing buffers designed to maintain the three-dimensional shape of the autoantigens. In one preferred embodiment, the substrate for the microarray is a nitrocellulose-coated glass slide.
The assays are performed by methods known in the art in which the one or more autoantigens are contacted with the biological sample under conditions that allow the formation of an immunocomplex of an autoantigen and an antibody, and detecting the immunocomplex. The presence and amount of the immunocomplex may be detected by methods known in the art, including label-based and label-free detection. For example, label-based detection methods include addition of a secondary antibody that is coupled to an indicator reagent comprising a signal generating compound. The secondary antibody may be an anti-human IgG antibody. Indicator reagents include chromogenic agents, catalysts such as enzyme conjugates, fluorescent compounds such as fluorescein and rhodamine, chemiluminescent compounds such as dioxetanes, acridiniums, phenanthridiniums, ruthenium, and luminol, radioactive elements, direct visual labels, as well as cofactors, inhibitors and magnetic particles. Examples of enzyme conjugates include alkaline phosphatase, horseradish peroxidase and beta-galactosidase. Methods of label-free detection include surface plasmon resonance, carbon nanotubes and nanowires, and interferometry. Label-based and label-free detection methods are known in the art and disclosed, for example, by Hall et al. (2007) and by Ray et al. (2010) Proteomics 10:731-748. Detection may be accomplished by scanning methods known in the art and appropriate for the label used, and associated analytical software.
In one preferred embodiment of the present invention, fluorescence labeling and detection methods are used to detect the immunocomplexes. Commericially available slide scanners (e.g. the Genepix 4000B slide scanner (Molecular Devices, Inc.) with associated analytical software may be used. In one preferred embodiment, the immunocomplex is probed with fluorescent-labeled (e.g., Alexa-Fluor (Invitrogen)) anti-human antibody and the intensity of fluorescence at each protein spot is measured using a microarray scanner. Commercially available software (e.g. GenePix Pro 5.0 software (Axon instruments)) may be used to extract the net median pixel intensities for individual features from the digital images produced by the scanner. Data may be normalized by comparing median values of multiple identical control spots in different regions of the same array.
Detection of immunocomplexes is indicative of the presence of neurodegenerative disease diagnostic autoantibodies in the biological sample, and thus a positive diagnosis of neurodegenerative disease.
Another embodiment of this invention provides a method for diagnosing a neurodegenerative disease in a subject comprising obtaining an immunoglobulin-containing biological sample from the subject, performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in a biological sample, and diagnosing said disease if one or more of the disease diagnostic autoantibodies is present.
In a preferred embodiment, the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Guillain-Barre syndrome, chronic peripheral neuropathy, optic neuritis, vascular dementia, obsessive compulsive disorder, Sydenham's chorea, PANDAS, Hashimoto's encephalopathy, schizophrenia, systemic lupus erythematosus, vascular cognitive disorders, stroke, Huntington's disease, neuromyelitis optica, paraneoplastic syndromes, limbic encephalitis, Rasmussen encephalitis, Hashimoto's encephalitis, encephalitis lethargica, stiff person syndrome, post-streptococcal movement disorders, rheumatic fever, gluten enteropathy, ASD, dyslexia, HTLV-1-associated myelopathy/tropical spastic paraparesis, myasthenia gravis, Lambert-Eaton syndrome, and arthrogryposis multiplex congenita.
In a preferred embodiment of the invention, the subject is a human.
In a preferred embodiment of the invention, the immunoglobulin-containing biological sample is serum, whole blood, CSF, saliva, or sputum. A blood sample may be obtained by methods known in the art including venipuncture or a finger stick. CSF may be obtained by methods known in the art including a lumbar spinal tap. To obtain serum from blood, a sample of blood is received and centrifuged at a speed sufficient to pellet all cells and platelets, and the serum to be analyzed is drawn from the resulting supernatant. Sputum and saliva samples may be collected by methods known in the art. The biological samples may be diluted with a suitable buffer.
In a preferred embodiment, the assay used for diagnosing a neurodegenerative disease in a subject is performed by contacting the sample with one or more autoantigens that are specific for a neurodegenerative disease diagnostic autoantibody under conditions that allow an immunocomplex of the autoantigen and the autoantibody to form, and detecting the presence of the immunocomplex, and is described in detail hereinabove. Autoantigens may provided in the form of an array, or preferably, a microarray.
Another embodiment of this invention includes a method of generating an subject-specific, neurodegenerative disease specific autoantibody profile comprising obtaining an immunoglobulin-containing biological sample from a subject, performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and generating a subject-specific neurodegenerative disease diagnostic autoantibody profile of the disease diagnostic autoantibodies present in the sample.
In a more preferred embodiment, the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Guillain-Barre syndrome, chronic peripheral neuropathy, optic neuritis, vascular dementia, obsessive compulsive disorder, Sydenham's chorea, PANDAS, Hashimoto's encephalopathy, schizophrenia, systemic lupus erythematosus, vascular cognitive disorders, stroke, Huntington's disease, neuromyelitis optica, paraneoplastic syndromes, limbic encephalitis, Rasmussen encephalitis, Hashimoto's encephalitis, encephalitis lethargica, stiff person syndrome, post-streptococcal movement disorders, rheumatic fever, gluten enteropathy, ASD, dyslexia, HTLV-1-associated myelopathy/tropical spastic paraparesis, myasthenia gravis, Lambert-Eaton syndrome, and arthrogryposis multiplex congenita.
In a preferred embodiment of the invention, the subject is a human.
In a preferred embodiment of the invention, the immunoglobulin-containing biological sample is serum, whole blood, CSF, saliva, or sputum. A blood sample may be obtained by methods known in the art including venipuncture or a finger stick. CSF may be obtained by methods known in the art including a lumbar spinal tap. To obtain serum from blood, a sample of blood is received and centrifuged at a speed sufficient to pellet all cells and platelets, and the serum to be analyzed is drawn from the resulting supernatant. Sputum and saliva samples may be collected by methods known in the art. The biological samples may be diluted with a suitable buffer.
In a preferred embodiment, the assay used to diagnose a neurodegenerative disease in a subject is performed by contacting the sample with one or more autoantigens that are specific for a neurodegenerative disease-specific autoantibody under conditions that allow an immunocomplex of the autoantigen and the antibody to form, and detecting the presence of the immunocomplex, and is described in detail hereinabove. Autoantigens may be provided in the form of an array, or preferably, a microarray.
Another embodiment of this invention provides a substrate on which one or more autoantigens that are specific for a neurodegenerative disease diagnostic autoantibody are immobilized. The present invention also provides, in another embodiment, a microarray comprising a substrate on which one or more autoantigens that are specific for a neurodegenerative disease diagnostic autoantibody are immobilized. The substrates and microarrays may be made as described hereinabove and are useful for creating neurodegenerative disease diagnostic autoantibody profiles and for the diagnosis of a neurodegenerative disease. An autoantigen may comprise a protein antigen, or a polypeptide or peptide fragment thereof containing one or more epitopes recognized by the disease diagnostic autoantibody, or an epitope peptidomimetic that is recognized by the disease diagnostic autoantibody. The substrates and microarrays contain at least one autoantigen specific for each neurodegenerative disease, and preferably contain from about two to about thirty autoantigens specific for each neurodegenerative disease.
The substrates and microarrays may contain a plurality of panels of autoantigens wherein each panel contains autoantigens that are diagnostic for a particular neurodegenerative disease. Such multi-substrates and multi-arrays allow the diagnosis of more than one neurodegenerative disease in the same assay, and also allow the differentiation of neurodegenerative diseases.
In a preferred embodiment, the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Guillain-Barre syndrome, chronic peripheral neuropathy, optic neuritis, vascular dementia, obsessive compulsive disorder, Sydenham's chorea, PANDAS, Hashimoto's encephalopathy, schizophrenia, systemic lupus erythematosus, vascular cognitive disorders, stroke, Huntington's disease, neuromyelitis optica, paraneoplastic syndromes, limbic encephalitis, Rasmussen encephalitis, Hashimoto's encephalitis, encephalitis lethargica, stiff person syndrome, post-streptococcal movement disorders, rheumatic fever, gluten enteropathy, ASD, dyslexia, HTLV-1-associated myelopathy/tropical spastic paraparesis, myasthenia gravis, Lambert-Eaton syndrome, and arthrogryposis multiplex congenita.
In a further embodiment, the present invention provides a kit for detecting neurodegenerative disease specific autoantibodies in a sample. The kit comprises one or more autoantigens that are specific for a neurodegenerative disease specific autoantibody and means for determining binding of the autoantigen to an autoantibody in the sample. The kit may also comprise packaging material comprising a label that indicates that the one or more autoantigens of the kit can be used for the identification of a neurodegenerative disease. Other components such as buffers, controls, detection reagents, and the like known to those of ordinary skill in art may be included in such the kits. The kits are useful for detecting neurodegenerative disease specific autoantibodies and for diagnosing neurodegenerative diseases.
Alzheimer's Disease
Alzheiner's disease (AD)-diagnostic autoantibodies are defined herein as antibodies that specifically bind to protein or peptide antigens and are diagnostic indicators that can be used to differentiate Alzheimer's Disease from control subjects without AD. Protein antigens that have been identified as being potentially useful diagnostic indicators are set forth in the following Table 1. The protein antigens in Table 1 are identified by art-accepted names as well as database identification numbers. The database identification numbers refer to the publically available protein databases of the National Center for Biotechnology Information (NCBI), which are well-known and accessible to those of ordinary skill in the art.
Drosophila); translocated to, 3 (MLLT3)
In another preferred embodiment, the substrate and microarrays may contain, as the autoantigen, at least one of the protein antigens of Table 2, or a polypeptide or peptide fragment thereof containing one or more epitopes recognized by the AD diagnostic autoantibody, or an epitope peptidomimetic that is recognized by the AD diagnostic autoantibody. The protein antigens in Tables 2-5 are identified by art-accepted names as well as database identification numbers. The database identification numbers refer to the publically available protein databases of the National Center for Biotechnology Information (NCBI) which are well-known and accessible to those of ordinary skill in the art.
In another embodiment, the substrate and microarrays may contain, as the autoantigen, at least one of the protein antigens of Table 3, or a polypeptide or peptide fragment thereof containing one or more epitopes recognized by the AD diagnostic autoantibodies, or an epitope peptidomimetic that is recognized by the AD diagnostic autoantibody.
In another embodiment of one aspect of the present invention, the microarray contains autoantigens consisting of FERM domain-containing protein 8 (FRMD8), 60S ribosomal protein L41(RPL41), pentatricopeptide repeat-containing protein 2 (PTCD2), and hematopoietic SH2 domain-containing protein (HSH2D) or fragments thereof containing one or more epitopes recognized by an AD diagnostic autoantibody, or epitope peptidomimetics that are recognized by the AD diagnostic autoantibody. In another embodiment, the microarray contains autoantigens consisting of FERM domain-containing protein 8 (FRMD8) and hematopoietic SH2 domain-containing protein (HSH2D) or fragments thereof containing one or more epitopes recognized by an AD diagnostic autoantibody.
In one preferred embodiment of the present invention, the substrate and microarrays may contain, as the autoantigen, at least one of the protein antigens of Table 4, or a fragment thereof containing one or more epitopes recognized by an AD diagnostic autoantibody, or an epitope peptidomimetic that is recognized by the AD diagnostic autoantibody. In another preferred embodiment of the present invention, the substrate and microarrays contain all of the protein antigens of Table 4.
Parkinson's Disease
In another embodiment of the present invention, the microarrays also contain autoantigens that are reactive with autoantibodies diagnostic for Parkinson's Disease (PD) but not for AD, and thus permit differentiation of AD from PD. Autoantigens diagnostic for PD but not AD include, for example, the proteins of Table 5, and fragments thereof containing one or more epitopes recognized by a PD diagnostic autoantibody and epitope peptidomimetics that are recognized by the PD diagnostic autoantibody.
The following examples serve to further illustrate the present invention.
Animals
Swiss-Webster mice were obtained from Taconic Farms (Hudson, N.Y.) and used for experiments at 3-6 months of age. Sprague-Dawley rats were also obtained from Taconic Farms and used at 7-9 weeks of age. Both were maintained on ad libitum food and water with 12-hour light/dark cycle in an AALAC-accredited vivarium. Animals use was reviewed and approved by the UMDNJ IACUC.
Human Brain Tissue
Brain tissue from patients with sporadic AD (n=23, age range=71-88) and age-matched, neurologically normal individuals (n=14, age range=69-83) were obtained from the Harvard Brain Tissue Resource Center (Belmont, Mass.), the Cooperative Human Tissue Network (Philadelphia, Pa.), the UCLA Tissue Resource Center (Los Angeles, Calif.) and Slidomics (Cherry Hill, N.J.). Post-mortem intervals were <24 h and pathological confirmation of AD was evaluated according to criteria defined by the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of AD (Hyman and Trojanowski (1997) J Neuropathol Exp Neurol 56, 1095-7). Formalin-fixed tissues were processed for routine paraffin embedding and sectioning according to established protocols. Control tissues exhibited minimal localized microscopic AD-like neuropathology.
Antibodies
Aβ42 antibodies were obtained from Millipore International (Temecula, Calif.,) (polyclonal, Cat. No. AB5078P, dilution=1:50) and Pharmingen (San Diego, Calif.) (polyclonal Cat. No. 4767, dilution=1:50). Biotinylated anti-human IgG antibodies for immunohistochemistry were obtained from Vector Laboratories (Burlingame, Calif.) (host: goat, Cat. No. PK-6103, dilution=1:100). Peroxidase-conjugated anti-human IgG antibodies for western blotting were obtained from Thermo Scientific (Rockford, Ill.) (host: goat, Cat. No. 31410, dilution=1:200,000). The following antibodies were used for treatments of mouse organotypic brain slice cultures: anti-alpha7 nicotinic acetylcholine receptor (C-20, Santa Cruz Biotechnology, Santa Cruz, Calif.); anti-GluR2 (polyclonal N19, Santa Cruz Biotechnology, Santa Cruz, Calif.); anti-beta tubulin (D-10, Santa Cruz Biotechnology, Santa Cruz, Calif.). The specificity of these antibodies was confirmed by western blotting.
Human Sera
Human serum samples [AD (n=52, age range=61-97 years); age-matched controls (n=28, age range=51-86); and younger healthy controls (n=28, age range=19-30 years)] were obtained from Analytical Biological Services Inc (Wilmington, Del.). Samples were numerically coded and included the following information: age and sex of the patient, the presence or absence of a detectable neurological disease and, if present, an indication of disease severity and estimated post-mortem interval. Use of these samples was approved by the UMDNJ IRB.
Immunohistochemistry
Immunohistochemistry was carried out using paraffin-embedded brain tissues as previously described (D'Andrea et al. (2001) Histopathology 38, 120-34; Nagele et al. (2002) Neuroscience 110, 199-211). Briefly, tissues were deparaffinized using xylene and rehydrated through a graded series of decreasing concentrations of ethanol. Antigenicity was enhanced by microwaving sections in citrate buffer. Endogenous peroxidase was quenched by treating sections with 0.3% H2O2 for 30 min. Sections were incubated in blocking serum and then treated with primary antibodies at appropriate dilutions for 1 hr at room temperature. After a thorough rinse in PBS, biotin-labeled secondary antibody was applied for 30 min. Sections were treated with the avidin-peroxidase complex (Vectastain ABC Elite, Vector Laboratories, Inc., Foster City, Calif.) and visualized with 3-3-diaminobenzidine-4-HCL (DAB)/H2O2 (Imm-Pact-DAB) (Vector). Sections were then lightly counterstained with hematoxylin, dehydrated through increasing concentrations of ethanol, cleared in xylene and mounted in Permount. Controls consisted of brain sections treated with non-immune serum or omission of the primary antibody. Specimens were examined and photographed with a Nikon FXA microscope, and digital images were recorded using a Nikon DXM1200F digital camera and processed and analyzed using Image Pro Plus (Phase 3 Imaging, Glen Mills, Pa.) and Cell Profiler image analysis softwares.
Preparation of Adult Rat Brain Proteins
To prepare rat brain protein fractions, fresh rat brain tissue was removed from storage at −80° C. and placed in a 1 mM phenylmethylsulfonyl fluoride, 50.0 mM Tris-HCL buffer solution, pH 7.4, at a 10.0 ml/g ratio along with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, Mo.) at a 0.5 ml/g ratio. Using a pre-cooled Dounce homogenizer (Arrow Engineering Co., Inc., Hillside, N.J.) at a setting of four, brain samples were subjected to homogenization. Brain samples were then centrifuged at 3,000 rpm using a Beckman CS-6R centrifuge (Beckman Coulter Inc, Brea, Calif.) equipped with a swing-rotor at 4° C. for a period of 10 min to remove intact cells and large debris. The supernatant was retained as whole brain protein fraction. Protein concentrations were determined using the Bradford Assay.
Detection of Autoantibody Targets Via Western Blotting
Western blot analysis was performed to determine the brain membrane targets of serum auto-antibodies. First, 12.5% SDS-polyacrylamide separating gels were cast using the Mini PROTEAN 3 System (165-3302, BioRad, Hercules, Calif.) and overlain with stacking gels (4.0%). 100.0 μg of protein sample was added to sample buffer and applied to the gel alongside PageRuler™ Prestained Protein Ladder Plus (SM1811, Fermentas, Glen Burnie, Md.). Proteins were then fractionated at 130V for 7 minutes, followed by 100V for the remainder of the resolving time. Proteins were then transferred to Hybond-ECL Nitrocellulose Membrane (RPN3032D, Amersham, Piscataway, N.J.) for 75 minutes at 180 mA. Blots were blocked in 5.0% non-fat dried milk dissolved in PBS-Tween (PBS-T) then transferred to human serum samples (primary antibody), diluted 1:500 in blocking solution, for overnight incubation at 4° C. The following morning, blots were thoroughly rinsed in PBS-T then placed in the appropriately diluted peroxidase-conjugated secondary antibody and incubated for one hour at 4° C. Blots were then thoroughly rinsed in PBS-T then quickly rinsed in dH2O to remove phosphate buffer. Blots were then developed using the Pierce enhanced chemiluminescence (ECL) substrate (32106, Pierce, Rockford, Ill.) and autoradiography film (XAR ALF 1824, Lab Scientific, Livingston, N.J.). Each western blot for a given serum sample was performed in triplicate.
Mouse Organotypic Brain Slice Cultures and Treatments
Organotypic adult mouse brain slice cultures (MBOCs) were prepared using the technique of Stoppini et al. (1991) J Neurosci Methods. 37, 173-82. Neurons in these cultures have been shown to accumulate exogenous Aβ42 (detectable within 4 h of exposure to 100 nM Aβ42) (Bahr et al., (1998) J Comp Neurol. 397, 139-47; Harris-White et al., (1998) J Neurosci. 18, 10366-74; Malouf, (1992) Neurobiol Aging. 13, 543-51; Stoppini et al. (1991)). Brains from Swiss-Webster mice (3-6 months old) were isolated under sterile conditions and transverse coronal slices (0.5-0.75 mm thick) through desired brain regions were prepared using a McIlwain tissue chopper, placed on 30 mm Millicell-CM culture inserts (Millicell-CM, Millipore, Bedford, Mass., USA), and allowed to stabilize in serum-free medium (DMEM) briefly (one hour) or in 25% inactivated horse serum, 25% Hanks' BSS, 50% DMEM, 25 mg/l penicillin-streptomycin) overnight prior to treatment. Following stabilization, cultures were exposed to serum-free medium (DMEM alone) or complete medium (25% inactivated horse serum, 25% Hanks' BSS, 50% DMEM, 25 mg/l penicillin-streptomycin) containing Aβ42 peptide (100 nM), anti-GluR2 antibody (diluted 1:250), human serum samples (diluted 1:50), anti-α7nAChR antibody (diluted 1:1000), anti-β-tubulin antibody (diluted 1:200). Control slices received medium only. MBOCs were treated for up to 72 h at 37° C. in a 5% CO2-enriched atmosphere. Aβ42 was solubilized to the monomeric form using the method of (Zagorski et al. (1999) Methods Enzymol. 309, 189-204).
Image Analysis
The extent of Aβ42 accumulation in MBOCs treated with 100 nM Aβ42 with or without human serum or antibodies directed against the α7nAChR or GluR2 was determined using quantitative immunohistochemistry. MBOCs treated as described above were first immunostained with anti-Aβ42 antibodies under identical conditions. Images were then recorded under identical illumination and camera settings using a Nikon FXA microscope equipped with a Nikon CCD camera and image analysis softwares (Image Pro Plus and Cell Profiler). Relative amounts of intracellular Aβ42-positive deposit per Aβ42-positive cell were determined and compared among the different treatment groups. The significance of differences in the amount of intracellular Aβ42 within cells were determined by the Student's t-test. Controls for immunohistochemistry included nonimmune serum or detection antibody only.
Sera from AD patients (n=52, age range 61-97 years), age-matched, non-demented control subjects (n=28, age range 51-86 years) and younger healthy individuals (n=28, age range 19-30 years) were tested for the presence of brain-reactive autoantibodies. For western analyses, individual sera were tested for the presence of brain-reactive autoantibodies by probing proteins obtained from whole cell homogenate derived from adult rat brain. Results confirmed the presence of brain-reactive autoantibodies in all sera from the three groups tested. The number of immunoreactive protein bands generated by each serum sample was similar for all three subject groups: mean=5.1±3.1 for AD sera (n=52); 7.4±4.0 for age-matched control sera (n=28); and 6.0±3.8 for younger healthy control sera (n=28). Comparable results were obtained when human sera were used to probe mouse and human brain proteins. Based on apparent molecular weights in western blots, a few potentially common protein bands were noted within and among the three subject groups.
Ig-positive neurons in postmortem AD brains have been reported (Bouras et al. (2005) Brain Res Brain Res Rev. 48, 477-87; Clifford et al. (2007) Brain Res. 1142, 223-36; Deane and Zlokovic (2007) Curr Alzheimer Res. 4, 191-7; Franceschi et al. (1989) J Gerontol. 44, M128-30; Kalaria (1999) Ann NY Acad Sci. 893, 113-125; Kulmala et al. (1987) Exp Aging Res 13:67-72; Loeffler et al. (1997) Neurochem Res. 22, 209-14; Mooradian (1988) Neurobiol Aging. 9, 31-9; Nandy et al. (1975) J Gerontol. 30, 269-74; Stein et al. (2002) J Neuropathol Exp Neurol. 61, 1100-8). In this example, immunohistochemistry using anti-human IgG antibodies was employed to test for the presence of IgG-immunopositive brain components in 23 AD and 14 age-matched control brains. IgG-positive neurons with immunolabeled cell bodies and dendrite trunks were found in all brains that were examined. IgG-positive neurons were far more abundant, widespread and intensely immunostained in AD brains than in corresponding age-matched control brains. In the latter, IgG-positive neurons were most often encountered as scattered individual cells and small cell clusters separated by relatively large expanses of brain tissue that were completely devoid of IgG-positive cells. In AD brains, IgG-positive neurons were particularly abundant in brain regions known to be vulnerable to AD-associated pathological changes (e.g., temporal cortex, entorhinal cortex and hippocampus). In both AD and control brains, IgG immunoreactivity was consistently and preferentially associated with pyramidal neurons, and these cells often showed marked individual variations in the intensity of IgG immunolabeling, sometimes with IgG-positive and -negative neurons present in close proximity. Similar variations in neuronal IgG immunostaining intensity were noted in neurons of the hippocampus. In pyramidal neurons, IgG immunoreactivity was most conspicuous in the cell body and proximal segment of the main dendrite trunk. Most of the smaller neurons, astrocytes and microglia that were interspersed among pyramidal cells were IgG-negative. In three of the 23 AD brains examined, both astrocytes and pyramidal neurons were IgG-positive, but this was not observed in age-matched control brains.
Sections of post-mortem AD brain tissue were probed with antibodies specific for human IgG and Aβ42. In regions of the cerebral cortex and hippocampus showing mild AD pathology (i.e., regions with sequestered intraneuronal Aβ42 deposits but few amyloid plaques), Aβ42-immunopositive neurons also exhibited intense IgG immunostaining. Two sets of consecutive sections were immunostained to reveal the relative distribution of Aβ42 and IgG in the cerebral cortex of AD brains. In regions exhibiting mild AD pathology, both IgG and Aβ42 were colocalized to the same neurons appearing in both sections. Likewise, in cortical regions showing more advanced pathology (as judged by the increased deposition of Aβ42 within neurons and amyloid plaques), the amount of interstitial and intraneuronal IgG was substantially increased. In addition to the typical large juxtanuclear deposits of Aβ42-rich material in pyramidal neurons, the main dendrite trunks of these cells frequently contained abundant small Aβ42-positive granules of uniform size. These results demonstrate the temporal and spatial coincidence of intraneuronal Aβ42 deposition and IgG immunolabeling within pyramidal neurons.
To test for the reactivity (i.e., binding) of human serum antibodies with the surfaces of living neurons, adult mouse brain organotypic (brain slice) cultures (MBOCs) were maintained in medium with or without diluted human serum for up to 72 h. MBOCs retain the adult brain histological architecture for up to several weeks under proper conditions and have been shown to contain neurons that internalize and accumulate exogenous, soluble Aβ42 peptide (Bahr et al. (1998); Harris-White et al. (1998); Malouf (1992); Stoppini et al. (1991). The binding of human IgG to neurons in MBOCs was detected by immunohistochemistry using anti-human IgG antibodies. Addition of human serum to the culture medium resulted in intense and selective IgG immunolabeling of living adult mouse neurons, whereas controls not treated with serum showed no inherent IgG immunoreactivity. The pattern of background IgG immunostaining in human serum-treated MBOCs suggests that dendrites and/or synaptic connections may also be IgG-positive. As was shown in postmortem human AD brains described above, pyramidal neurons of the cerebral cortex of MBOCs were consistently the most intensely immunopositive cells.
This example utilizes the property of cross-reactivity of the antibodies in human serum with rodent brain proteins as demonstrated above in western blots and in brain tissue as shown above in immunohistochemical preparations. MBOCs were treated with 100 nM Aβ42 in the presence or absence of individual human serum samples diluted 1:50 in otherwise serum-free medium for 1, 3, 24, 48 and 72 h and the relative amounts of intraneuronal Aβ42 were quantified using image analysis for MBOCs treated for 24 h. MBOCs treated with 100 nM Aβ42 alone for 24 h showed no human IgG immunostaining and only minimal Aβ42 immunoreactivity. On the other hand, when MBOCs were exposed to human serum autoantibodies and Aβ42 peptide for 24 h, pyramidal neurons selectively showed a dramatic increase in intracellular Aβ42 accumulation over that of controls treated with Aβ42 peptide or serum alone for the same time period. Within these neurons, Aβ42-positive material was localized to dense cytoplasmic granules that were concentrated in the neuronal perikaryon and proximal dendrite trunk. Measurements of the relative amounts of intraneuronal Aβ42 in MBOCs using image analysis after 24 h of treatment revealed that the addition of human serum to medium containing 100 nM Aβ42 caused a many-fold increase in neuronal Aβ42 immunoreactivity over that in cells treated with Aβ42 alone. Morphological evidence of significant cell death and loss of Aβ42-burdened neurons in MBOCs was not observed.
MBOCs were treated for 24 h with commercially available antibodies directed against two neuronal receptors that are known to be abundantly expressed on neuronal cell surfaces, the alpha7 nicotinic acetylcholine receptor (α7nAChR) and the glutamate R2 (GluR2) receptor. Both antibodies were found to be effective in increasing intraneuronal Aβ42 accumulation, again selectively in pyramidal neurons and well above levels seen in cultures treated with Aβ42 alone. To explore whether neuronal cell surface reactivity of IgG is required for enhancement of exogenous Aβ42 internalization, MBOCs were also treated with an antibody directed against the common intracellular protein, beta-tubulin, along with 100 nM Aβ42. Treatment with beta-tubulin antibody resulted in levels of neuronal Aβ42 accumulation that were comparable to treatment with 100 nM Aβ42 alone.
Western Analysis
As disclosed hereinabove, biochemical confirmation of the presence of brain-reactive autoantibodies in individual human sera was carried out using western analysis. In addition, total rat brain protein, which is immunoreactive to human autoantibodies as shown hereinabove, was used to compare sera from patients with AD, age-matched neurologically normal controls and younger healthy individuals. Based on estimated molecular weights alone, the resulting distributions of molecular weights for individual target proteins were analyzed using the pattern recognition computer program called A.I. Solver (Silversoft Solutions).
Based on the recognition of specific patterns of distribution of molecular weights of autoantibody target proteins, A.I. Solver was able to distinguish western blots derived from AD patient's sera from that of age-matched controls and younger healthy subjects 98% of the time. This example demonstrates the existence of AD-specific protein antibodies in the blood that bind to brain protein target antigens. Next, a protein microarray platform was used identify the specific subset of autoantibodies and their target proteins that are useful to effectively diagnose AD.
Micrarray Procedure
The protein microarray platform used to identify diagnostic antibodies and prove the efficacy of a protein microarray diagnostic was Invitrogen's ProtoArray® Human Protein Microarray v5.0. It is a high-density protein microarray containing thousands of purified human proteins for protein interaction screening. Each human open reading frame (ORF) is expressed as an N-terminal GST fusion protein using a baculovirus expression system, purified from insect cells, and printed in duplicate on a nitrocellulose-coated glass slide. The Immune Response Biomarker Profiling application was used as it is best suited the needs of a diagnostic. All reagents and materials were purchased directly through Invitrogen. The recommended Invitrogen ProtoArray® protocol was strictly adhered to at all times and is incorporated herein by reference in its entirety. The array was probed with diluted (1:500) human serum or plasma.
Microarray Scanning
The protein microarrays were scanned using the recommended Axon Genepix 4000b imager. Individual slides were inserted into the imager and then scanned using 100% laser power, 635 nm excitation wavelength, PMT 600, and Sum pixel size. Data was extracted from the image by syncing it with a Genepix Array List (.GAL) file obtained from Invitrogen. GAL files describe the location and identity of all spots on the protein microarray and are used by Genepix Pro software (by Molecular Devices) to generate files that contain pixel intensity information for all features on the array. Genepix Pro then creates a .GPR (Genepix Pixel Results) file that lists all of the pixel intensity data for each protein spot on the microarray in text-only spreadsheet format. It is the GPR file that is imported into Prospector for data analysis.
Normalization
After acquiring the individual microarray data by scanning the microarrays with an Axon Genepix 4000b imager and performing the initial quantification with Genepix Pro software, the resulting data were normalized so as to allow microarray-to-microarray comparison. For this, Invitrogen's proprietary software, Prospector; more specifically, the Immune Response Biomarker Profiling Toolbox application, was used. Each microarray's gpr file was imported into the program, analyzed, and normalized to a linear model.
Fitting the data to a linear model was performed through a robust regression by means of an iteratively re-weighted least-square procedure with an M-estimator, like the median. The linear model uses log-transformed signals to estimate and correct the variations. For each spot replicate r (=1,2) of protein feature k (=1, . . . ,nf) in sub-array j (=1, . . . ,48) on slide i (=1, . . . ,ns,) the following model was fit:
yijkr=αi+βj+τk+εijkr
where yijkr is the observed signal in log 2 scale, α is the slide effect, βj is the sub-array/block effect (including printing pin effect), τk is the “true” signal of the protein feature (different protein content printed in different concentration), and εijkr is the error, assuming εijkr˜N(0,σ1). After the coefficients of these effects were estimated using control proteins, the normalized signal in its original scale for each spot was calculated as:
Sijkr=2{circumflex over ( )}(yijkr−αi−βj)
After normalization, the microarray data was fully adjusted for error and individual variation; formal analysis was begun. It was this adjusted data from which diagnostic significance was determined.
Data Analysis
There are multiple accepted methods of determining the diagnostic significance of microarray fluorescence data. To ensure the reproducibility and accuracy of our results, data were analyzed three separate times using three independent and distinct methods. The methods chosen are among the most reliable and consistent available, and are commonly used in similar studies. The methods are: M-Statistical Prevalence, Nearest Shrunken Centroid Analysis, and Random Forest Decision-Making Trees. To harness each of these unbiased statistical quantification schemes, Prospector, PAM, and R's Random Forest, respectively, were utilized. Each of these programs evaluated the protein microarray data to determine which proteins were most significant to diagnose Alzheimer's Disease. The lists reflected one another almost exactly, thus demonstrating that protein microarrays are useful as a successful diagnostic. The statistical methods, programs involved, and results generated are described below.
M-Statistical Analysis
As well as interpreting and normalizing the raw fluorescence data generated by Genepix Pro, Prospector was used to generate M-Statistics that were, in turn, used to evaluate each protein's diagnostic significance. Briefly, M-statistics were used to determine the number of assays in one group (e.g. Alzheimer's or Control) that have a signal value for a protein greater than the highest observed signal value of this probe in the comparison group. The M order statistic for the group y of size ny compared to group x of size nx is given by the formula:
Myi,above,between=Σ1{yk>x(i)+between}1{yk>above}
where x(i) is the ith largest value of the group x, and above and between are the calculation parameters. A p-value was calculated as the probability of having M value greater or equal than Mi. Prospector selected the M statistic with the lowest p-value and reported this Mmax value and order, as well as a corresponding p-value and protein prevalence estimate. The values were viewed as a spreadsheet in Microsoft Excel Workbook format, and filtered to provide a list of the most effective indicators of group differences, i.e., the proteins that are the best diagnostic markers.
PAM (Prediction Analysis of Microarrays)
Another method of interpreting protein microarray results and yielding protein significance is PAM, or Prediction Analysis of Microarrays. PAM is a statistical technique for class prediction that uses nearest shrunken centroids. It is run as a Microsoft Excel Macro and has been used extensively in characterizing microarray results (Tibshirani et al. (2002) Proc Natl Acad Sci USA 99:6567-6572). The program was used to identify specific subsets of fluorescence data that best characterize each class and thus serve as significant diagnostic indicators. Briefly, the method computed a standardized centroid for each class. This is the average fluorescence for protein in each class divided by the within-class standard deviation for that protein. Centroids were “shrunken”—reduced by a threshold value—to reduce error and outlier effect. The microarray fluorescence of each new sample was then compared to each shrunken class centroid; the class whose centroid that it was closest to, in squared distance, was the predicted class for that new sample. Using this information, PAM generated a list of proteins presented in order of diagnostic significance.
PAM was used to produce a list of the top fifty most important proteins for distinguishing Alzheimer's Disease sera from Control Sera which is shown below in Table 6.
The third quantitative method that was used to corroborate the results was Random Forest. This is an open-source classification algorithm, run through R, that uses an ensemble of decision-making trees. Each of these classification trees was built using a bootstrap sample of the data, and at each split the candidate set of variables was a random subset. Random Forest directly returned several measures of variable significance, which were related to the relevance of the variable in the classification. Hence, in this case, it provided an evaluation of each protein's relative importance to proper diagnosis.
The most reliable measure was based on the decrease of classification accuracy when values of a variable in a node of a tree were permuted randomly and this was the measure of variable importance. Another estimation of significance of a variable was based on Gini impurity. Every time a split of a node was made on variable m the Gini impurity criterion for the two descendent nodes was less than the parent node. Adding up the Gini decreases for each individual variable over all trees in the forest gave a fast variable importance that is often very consistent with the permutation importance measure.
The Relative Fluorescence Unit value for each protein spot on the microarray, as calculated by Genepix Pro and Prospector, was imported into Random Forest. The prediction model was performed using the R package and all default settings—as is proscribed for the best microarray analysis results. Calculating an average Out-Of-Bag Error of only 6.67%, the algorithm was able to quickly evaluate protein significance based on the evaluation methods described above.
Results
Three different, unbiased statistical methods were used to evaluate the diagnostic significance of individual autoantibodies in the microarray data and they reflected one another almost perfectly. The three resultant lists considered the same autoantibodies diagnostically important, and assigned them similar significance. The shared conclusions of all three lend the results great confidence. The list of all of the protein antigens determined by these methods that have autoantibodies that can be used as indicators for Alzheimer's disease is shown below in Table 7. Included is the protein database identification number, the open reading frame number, the common name for each protein, its disease-state indication, and the relevant p-value as calculated by the M-statistic.
cerevisiae) (ELOF1)
coli) (NEIL1)
cerevisiae) (DUS1L)
cerevisiae) (POP5), transcript
cerevisiae) (DUS3L)
pombe) (CHEK1)
laevis) (MIER1)
Using a small subset of the identified indicators, it was possible to diagnose AD with great efficiency. The twenty protein microarray fluorescence values depicted in Table 4 were used to classify blinded samples as either Alzheimer's or control. A threshold value was calculated for each diagnostic indicator using the following equation:
Diagnostic Threshold=[(Mean AD Fluorescence Value)−(Mean Control Fluorescence Value)/2]+(Mean Control Fluorescence Value)
A fluorescence value for any given diagnostic indicator over the threshold value for that indicator is scored as a positive result. Using the antigens from Table 4, greater than or equal to four positive results out of the possible twenty diagnostic indicators predicts with high accuracy that the sample is from an Alzheimer's Disease patient. Less than four positive results out of the possible twenty diagnostic indicators on Table 4 predicts with high accuracy that the sample is from a healthy Control. (See
Alzheimer's Disease (AD) vs. All Controls
(Using twenty biomarkers from Table 4), (See
N=90 (50 AD, 40 Control), Overall Error Rate: 4.44%
Twenty antibodies and their respective antigens were selected that were rated as highly significant by multiple statistical analysis programs (Prospector, PAM, Random Forest) and performed well in a single platform. The antibodies are listed in Table 8.
With these twenty biomarkers (listed in Table 4 and Table 8) and the simple diagnostic logic explained above, it was possible to differentiate Alzheimer's Disease serum samples from Control serum samples with over 95% efficiency.
It is also possible to accurately diagnose using only the four biomarkers from Table 3. Diagnostic efficiency for these diagnostic indicators was assessed for AD, low Mini-Mental Status Examination (MMSE) AD and high-MMSE AD. The results are shown below.
Alzheimer's Disease (AD) vs. All Controls
Random Forest:
N=90 (50 AD, 40 Control), Overall Error Rate: 7.78%
Predictive Analysis of Microarrays (PAM):
N=90 (50 AD, 40 Con), Overall Error Rate: 7.8%
Low-MMSE AD vs. All Controls
(Low-MMSE AD samples have MMSE<15)
Random Forest:
N=55 (15 Low-MMSE AD, 40 Control), Overall Error Rate: 7.26%
Predictive Analysis of Microarrays (PAM):
N=30 (15 Low-MMSE AD, 15 Control), Overall Error Rate: 9.9%
High-MMSE AD vs. All Controls
(High-MMSE AD samples have MMSE>15)
Random Forest:
N=75 (35 High-MMSE AD, 40 Control), Overall Error Rate: 10.67%
Predictive Analysis of Microarrays (PAM):
N=70 (35 High-MMSE AD, 35 Control), Overall Error Rate: 12.8%
Using a combination of the biomarkers listed in Tables 3 and 5 (totaling nine diagnostic indicators), the efficiency of distinction between AD and Parkinson's Disease was also assessed. The results are shown below.
Alzheimer's Disease (AD) vs. Parkinson's Disease (PK)
Random Forest:
N=79 (29 AD, 29 PK), Overall Error Rate: 12.07%
Predictive Analysis of Microarrays (PAM):
N=58 (29 AD, 29 PK), Overall Error Rate: 12.0%
It was determined that it was possible to differentiate AD and control with over 95% accuracy using the twenty antigens from Table 4 and over 90% accuracy using the four antigens on Table 3, however, the use of only these four indicators did not allow accurate differentiation of Alzheimer's Disease from other neurodegenerative diseases like Parkinson's Disease. Accurate differentiation requires the inclusion of antigens from Table 5. In practice, however, this distinction is often unnecessary, since patients presenting with suspected Alzheimer's disease come with memory and cognitive deficits, whereas patients with early Parkinson's most often show tremors with no complaints of cognitive and/or memory deficits.
All references cited herein are incorporated by reference herein in their entireties.
The present application is a continuation of U.S. patent application Ser. No. 15/606,653, filed May 26, 2017, which is a continuation of U.S. patent application Ser. No. 13/697,601, filed Feb. 27, 2013, now issued as U.S. Pat. No. 9,664,687, which is a 35 U.S.C. § 371 national phase application of, and claims priority to, International Application No. PCT/US11/30883, filed Apr. 1, 2011, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 61/334,466, filed May 13, 2010 and U.S. Provisional Patent Application No. 61/444,932, filed Feb. 21, 2011, all of which applications are incorporated herein by reference in their entireties.
| Number | Name | Date | Kind |
|---|---|---|---|
| 9664687 | Nagele | May 2017 | B2 |
| 20030068659 | Kilgannon et al. | Apr 2003 | A1 |
| 20050112116 | Lennon et al. | May 2005 | A1 |
| 20080254482 | Mattoon et al. | Oct 2008 | A1 |
| 20100035360 | Mikoshiba | Feb 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 109738653 | May 2019 | CN |
| 0210753 | Feb 2002 | WO |
| 2005019828 | Mar 2005 | WO |
| 2006067792 | Jun 2006 | WO |
| 2006121912 | Nov 2006 | WO |
| 2008122432 | Oct 2008 | WO |
| 2010028248 | Mar 2010 | WO |
| 2011028912 | Mar 2011 | WO |
| 2013023144 | Feb 2013 | WO |
| Entry |
|---|
| Stoppini et al., A simple method for organotypic cultures of nervous tissue, J. of Neuroscience Methods, 37 ;1991) 173-182. |
| Bahr et al., Amyloid b Protein is Internalized Selectively by Hippocampal Field CA1 and Causes Neurons to Accumulate Amyloidogenic Carboxyterminal Fragments of the Amyloid Precursor Protein, J. Of Comparative Neurology 397:139-147 (1998). |
| Harris-White et al., Effects of Transforming Growth Factor-b (Isoforms 1-3) on Amyloid-b Deposition, Inflammation, and Cell Targeting in Organotypic Hippocampal Slice Cultures, J. Or Neuroscience, Dec. 15, 1998, 18(24): 10366-10374. |
| Nakamura et al., Proline Isomer-Specific Antibodies Reveal the Early Pathogenic Tau Conformation in Alzheimer's Disease, Cell Mar. 30, 2012; 149(1): 232-244. |
| Wang et al., Proteomic identification of biomarkers of traumatic brain injury, Expert Rev. Proteomics 2(4), (2005). |
| Parnetti et al., Cerebrospinal Fluid Tau/c-Synuclein Ratio in Parkinson's Disease and Degenerative Dementias, Movement Disorders, vol. 26, No. 8, 2011. |
| Kuusisto et al., Use of p62/SQSTM1 antibodies for neuropathological diagnosis, Neuropathology and Applied Neurobiology (2008), 34, 169-180. |
| Holzer et al., Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus, Acta Neuropathol (2002) 104: 471-481. |
| Tomic et al., Soluble Fibrillar Oligomer Levels are Elevated in Alzheimer's Disease Brain and Correlate with Cognitive Dysfunction, Neurobiol Dis. Sep. 2009; 35(3): 352-358. |
| Kulmala et al., “Brain reactive antibodies and the blood-brain barrier: observations in again rodents and the effects of peripheral kainic acid,” Exp Aging Res (1987); 13:67-72 Abstract Only. |
| Kemper et al., “Neuropathology of Infantile Autism,” Journal of Neuropathology and Experimental Neurology (Jul. 1998); 57(7):645-652. |
| American Psychiatric Association: Diagnosis and Statistical Manual of Metnal Disorders, Fourth Edition (2000); pp. 1-951. |
| Mooradian, Arshag D., “Effect of Aging on the Blood-Brain Barrier,” Neurobiology of Aging (1988); 9:31-39. |
| Gamblin et al., “Modeling Tau Polymerization in Vitro: A Review and Synthesis,” Biochemistry (Dec. 30, 2003); 42(51):15009-15017. |
| Moudjou et al., “Cellular prion protein status in sheep: tissue-specific biochemical signatures,” Journal of General Virology (2001); 82:2017-2024. |
| Delacourte et al., “Vulnerable Neuronal Subsets in Alzheimer's and Pick's Disease Are Distinguished by Their t Isoform Distribution and Phosphorylation,” Annals of Neurology (Feb. 1998); 43(2):193-204. |
| Kerman et al., “Amyotrophic lateral sclerosis in a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form,” Acta Neeuropathol (2010); 119:335-344. |
| Korolainen et al., “Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain,” Neurobilogy of Disease (2005); 20:858-870. |
| Kinoshita et al., “Identification of Septins in Neurofibrillary Tangles in Alzheimer's Disease,” American Journal of Pathology (Nov. 1998) 153(5):1551-1560. |
| Lai et al., “Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a : ase series,” Lancet Neurol. (Aug. 2010); 9(8):776-785. |
| Licker et al., “Proteomics in human Parkinson's disease research,” Journal of Proteomics (2009); 73:10-29. |
| Korolainen et al., “Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain,” Neurobilogy of Aging (2006); 27:42-53. |
| Bailey et al., “Autism as a strongly genetic disorder: evidence from a British twin study” Psychol Med (1995); 25(1):63-77 Abstract Only. |
| Deane et al., “Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimer's Disease,” Current Alzheimer Research (2007); 4(2):191-197 Abstract Only. |
| Franceshci et al., “Neuron-Binding Antibodies in Alzheimer's Disease and Down's Syndrome,” Journal of Gerontology (1989) 44(5):M128-M130 Abstract Only. |
| Nandy et al., “Specificity of brain-reactive antibodies in serum of old mice,” J. Gerontol. (1975); 30:269-74 Abstract Only. |
| Roche et al., J Immunol Methods, 338, 2008, p. 75-78. |
| Yanamandra, et al. a-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One. Apr. 25, 2011. 6(4):e18513. |
| Han. et al. Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera. PLoS One ePub Feb. 22, 2012, 7(2):e32383. |
| Nagele. et al. Brain reactive autoantibodies prevalent in human sera increase intraneuronal amyloid beta 1-42 deposition. J Alzheimers Dis Apr. 2011. 25(4):605-622. |
| Nagele et al. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One ePub Aug. 3, 2011, 6(8):e23112. |
| Wuchty et al. “Prediction of Associations between microRNAs and Gene Expression in Glioma Biology”, PlosONE; Feb. 16, 2011; vol. 6, No. 2; p. 1-10. |
| Nelson “Alzheimer Pathology in Elderly Patients With Glioblastoma Multiforme”; Arch Pathol Lab Med; Dec. 2002; vol. 126; p. 1515-1517. |
| K. Yanagawa et al: “Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis”, Neurology, vol. 73, No. 20, Nov. 17, 2009, pp. 1628-1637. |
| Vernino Steven et al: “Autoimmune encephalopathies”, Neurologist, vol. 13, No. 3, May 1, 2007, pp. 140-147. |
| Life Technologies Corporation, Absolute identification of novel autoimmune biomarkers ProtoArray.RTM. Human Protein Microarrays, published 2009. Retrievedonline <https://www.lifetechnologies.com/us/en/home/life-science/protein-biol- ogy/protein-assays-analysis/protein-microarrays/immune-response-biomarker- profiling-irbp.html> Retrieved on Jul. 27, 2015. |
| Selkoe, Dennis J., Alzheimer's Disease Is a Synaptic Failure, Science, vol. 298, Oct. 25, 2002, pp. 789-791. |
| Schwab et al., Inflammatory Aspects of Alzheimer Disease and Other Neurodegenerative Disorders, J. of Alzheimer's Disease 13 (2008) 359-369. |
| Thal et al, Cerebral amyloid angiopathy and its relationship to Alzheimer's disease, Acta Neuropathol (2008) 115:599-609. |
| Weisman et al., Interleukins, Inflammation, and Mechanisms of Alzheimer's Disease, Vitamins and Hormones, vol. 74 (2006) pp. 505-530. |
| D'Andrea et al., Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease, Histopathology 2001, 38, 120-134. |
| Nagele et al., Intracellular Accumulation of b-Amyloid 1-42 in Neurons is Facilitated by the a7 Nicotinic Acetylcholine Receptor in Alzheimer's Disease, Neuroscience vol. 110, No. 2, pp. 199-211, 2002. |
| Gouras et al., Intraneuronal Ab42 Accumulation in Human Brain, American Journal of Pathology, vol. 156, No. 1, Jan. 2000 p. 15-20. |
| Stein et al., Circulating Autoantibodies Recognize and Bind Dying Neutons Following Injury to the Brain, J. Of Neuropathology and Experimental Neurology, Dec. 2002, vol. 61, No. 12, pp. 1100-1108. |
| Bouras et al., Humoral immunity in brain aging and Alzheimer's disease, Brain Research Reviews 48 (2005) 477-487. |
| D'Andrea, Michael R., Evidence linking neuronal cell death to autoimmunity in Alzheimer's disease, Brain Research 982 (2003) 19-30. |
| Mecocci et al., Antihistone and Anti-dsDNA Autoantibodies in Alzheimer's Disease and Vascular Dementia, Biol Psychiatry (1993), 33, 380-385. |
| Mecocci et al., Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia, J. of Neuroimmunology 57 (1995) 165-170. |
| Weksler et al., “Do age-associated changes in ‘physiologic’ autoantibodies contribute to infection, atherosclerosis, and Alzheimer's disease?”, Experimental Gerontology 37 (2002) 971-979. |
| Fombonne, Eric, The Prevalence of Autism, JAMA, Jan. 1, 2003, vol. 289, No. 1, pp. 87-88. |
| Palmer et al., Neuropathological findings in autism, Brain (2004) 127, 2572-2583. |
| Acosta et al., Imaging Data in Autism: From Structure to Malfunction, Semin Pediatr Neurol 11: 205-213. |
| Jung et al., Analysis and Visualization of Single-Trial Event-related Potentials, Human Brain Mapping 14:166-185 ;2001). |
| Ashwood et al., The immune response in autism: A new frontier for autism research, J. Of Leukocyte Biology, Aug. 2006 pp. 1-15. |
| Wills et al., Autoantibodies in Autism Spectrum Disorders (ASD), Ann. N.Y. Acad. Sci. 1107: 79-91 (2007). |
| Zimmerman et al., Maternal antibrain antibodies in autism, Brain, Behavior, and Immunity 21 (2007) 351-357. |
| Singh et al., Prevalence of serum antibodies to caudate nucleus in autistic children, Neuroscience Letters 355 ;2004) 53-56. |
| Hallett et al., Anti-striatal antibodies in Tourette syndrome cause neuronal dysfunction, J. of Neuroimmunology 111 (2000) 195-202. |
| Swedo et al., Identification of Children with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections by a Marker Assocaited with Rheumatic Fever, Am J Psychiatry 154:1, Jan. 1997. |
| Kalume et al., Molecular Mimicry: Cross-Reactive ANtibodies from Patients with Immune-Mediated Neurologic Disease Inhibit Neuronal Firing, J. of Neuroscience Research 77:82-89 (2004). |
| Tanaka et al., Effects of antineuronal antibodies from patients with paraneoplastic neurological syndrome on primary-cultured neurons, J. of Neurological Sciences 217 (2004) 25-30. |
| DeGiorgio et al., A subset of lupus anti-dna antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nature Medicine vol. 7, No. 11, Nov. 2001, 1189-1193. |
| Kowal et al., Cognition and Immunity: Antibody Impairs Memory, Immunity, vol. 21, 179-188, Aug. 2004. |
| Tibshirani et al., Diagnosis of multiple cancer types by shrunken centroids of gene expression, PNAS, May 14, 2002, vol. 99, No. 10, 6567-6572. |
| Hall et al., Protein Microarray Technology, Mech Ageing Dev. Jan. 2007; 128(1): 161-167. |
| Stoevesandt et al., Protein microarrays: high-throughput tools for proteomics, Expert Rev. Proteomics 6(2), 145-157(2009). |
| Venkataraman et al., Neurocalcin d Modulation of ROS-GC1, a New Model of Ca2+Signaling, Biochemistry Jun. 24, 2008; 47 (25): 6590-6601. |
| Li et al., Expression of Recombinant Proteins in Pichia Pastoris, Appl Biochem Biotechnol (2007) 142:105-124. |
| Altmann et al., Insect cells as hosts for the expression of recombinant glycoproteins, Glycoconjugate Journal 16, 109-123 (1999). |
| Spampinato et al., Agonist-Regulated Internalization and Desensitization of the Human Nociceptin Receptor Expressed in CHO Cells, Current Drug Targets, 2007, 8, 137-146. |
| Ramachandran et al., On-chip protein synthesis for making microarrays, Methods in Molecular Biology, Feb. 2006, pp. 1-15. |
| He et al., In situ synthesis of protein arrays, Current Opinion in Biotechnology 2008, 19:4-9. |
| He et al., Single step generation of protein arrays from DNA by cell-free expression and in situ immobilisation (PISA method), Nucleic Acids Research, 2001, vol. 29, No. 15 e73. |
| Ramachandran et al., Self-Assembling Protein Microarrays, Science Jul. 2, 2004, vol. 305, pp. 86-89. |
| He et al., Printing protein arrays from DNA arrays, Nature Methods, vol. 5, No. 2, Feb. 2008, pp. 175-177. |
| Ray et al., Label-free detection techniques for protein microarrays: Prospects, merits and challenges, Proteomics 2010, vol. 10, pp. 731-748. |
| Zabouo et al. CD146 expression is associate with a poor prognosis iin human breast tumors and with enhanced motility in breast cancer cell lines, Breast Cancer Research, Current Medicine Group Ltd., GB, vol. 11, No. 1, Jan. 5, 2009. |
| Sharma et al., Mimicking the functional hematopoietic stem cell niche in vitro: recapitulation of marrow physiology by hydrogel-based three-dimensional cultures of mesenchymal stromal cells, Haematologica, vol. 97, No. 5, Nov. 4, 2011, pp. 651-660. |
| Park et al., Glutaric Aciduria Type 1 in Korea: Report of Two Novel Mutations, Journal of Korean Medical Sciences, vol. 25, No. 6, Jan. 1, 2010, p. 957. |
| Strausberg et al., Generation and initial analysis of more then 15,000 full-length human and mouse cDNA sequences, Proceedings fo the National Academy of Science, vol. 99, No. 25, Dec. 24, 2002, pp. 16899-16903. |
| Extended European Search Report for European Application No. 21198186.5, filed Sep. 22, 2021 dated Feb. 28, 2022. |
| Number | Date | Country | |
|---|---|---|---|
| 20190302125 A1 | Oct 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61444932 | Feb 2011 | US | |
| 61334466 | May 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15606653 | May 2017 | US |
| Child | 16435483 | US | |
| Parent | 13697601 | US | |
| Child | 15606653 | US |
